Madison El-Saadi

Madison El-Saadi, Ph.D., is a healthcare equity research analyst at B. Riley Securities, Inc. He joined the B. Riley healthcare team in 2022, where his research coverage includes smid-cap biotech companies in the neuroscience, rare disease, vaccine, and RNA-based therapeutic sectors. Prior to B. Riley, Dr. El-Saadi was in equity research at Raymond James, focusing on neuroscience and rare disease therapeutic areas.

Before joining Wall Street, he was a Fellow at the Texas Institute for Restorative Neurotechnologies (TIRN), where he explored innovative therapies for neurodevelopmental and neurodegenerative disorders. Dr. El-Saadi also conducted research at McGovern Medical School in a joint program with MD Anderson. He earned his Ph.D. in neuropharmacology from the Louisiana State University School of Graduate Studies and completed postdoctoral work at the University of Texas Health Science Center at Houston.